<DOC>
	<DOCNO>NCT00003444</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Interferon alfa-2b may interfere growth cancer cell . It yet know whether give radiation therapy interferon alfa-2b effective give interferon alfa-2b alone treat melanoma . PURPOSE : Randomized phase III trial compare effectiveness radiation therapy plus interferon alfa-2b interferon alfa-2b alone treat patient melanoma metastasize lymph node neck , arm , groin .</brief_summary>
	<brief_title>Interferon Alfa-2b With Without Radiation Therapy Treating Patients With Melanoma That Has Metastasized Lymph Nodes Neck , Under Arm , Groin</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate effectiveness postoperative hypofractionated radiotherapy combination high dose interferon prevent regional relapse patient malignant melanoma number node clinical extracapsular extension previous nodal basin recurrence . II . Evaluate effectiveness therapy prolong relapse free overall survival patient population . III . Evaluate toxicity therapy patient population . OUTLINE : This randomize study . Patients stratify accord prior nodal basin recurrence , site disease , extracapsular extension . Following surgery , patient randomize receive either interferon alfa-2b alone five treatment radiotherapy follow interferon alfa-2b . Patients receive radiotherapy 2 day week 2.5 week . Patients receive interferon alfa-2b IV 20 minute daily 5 day total 28 day , follow subcutaneous injection 3 time week 48 week . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : Approximately 167 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically document malignant melanoma node ( ) meet one follow criterion : 1 lymph node find contain metastatic melanoma gross evidence extracapsular nodal extension Nodal recurrence site previous lymphadenectomy All gross cancer remove negative margin Prior node biopsy allow complete nodal dissection perform Parotid involvement outside node allow No distant metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm3 Platelet count least 125,000/mm3 Hematocrit least 33 % Hepatic : AST great 2 time upper limit normal ( ULN ) LDH great 2 time ULN Alkaline phosphatase great 2 time ULN Bilirubin great 2 time ULN If LDH alkaline phosphatase normal , CT MRI liver require Renal : Creatinine great 1.8 mg/dL BUN great 33 mg/dL Other : Not pregnant nursing Fertile patient must use effective contraception No prior concurrent malignancy within 2 year , except carcinoma situ , lobular carcinoma breast situ , carcinoma situ cervix , atypical melanocytic hyperplasia Clark I melanoma situ , basal squamous cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No prior interferon Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy head neck , axillary , inguinal area Surgery : See Disease Characteristics Recovered prior surgery</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>stage III melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>